Key slide by MEDraysintell used at the SNMMI virtual meeting 2021 to show the anticipated impact of radiotheranostics. As mentioned by our US Ambassador Jean-Luc Vanderheyden, the field is “here to stay” now, with many new isotopes (including targeted alphas), new entities and new technologies. The Oncidium foundation supports the development of radiotheranostics for cancer care, keeping in mind that access, costs and readiness are the three main objectives to reach for effective use of these technologies, globally.